Oxetorone fumarate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596566

CAS#: 34522-46-8 (fumarate)

Description: Oxetorone fumarate is a serotonin antagonist, antihistamine, and alpha blocker used as an antimigraine drug.

Chemical Structure

Oxetorone fumarate
CAS# 34522-46-8 (fumarate)

Theoretical Analysis

MedKoo Cat#: 596566
Name: Oxetorone fumarate
CAS#: 34522-46-8 (fumarate)
Chemical Formula: C25H25NO6
Exact Mass: 0.00
Molecular Weight: 435.470
Elemental Analysis: C, 68.95; H, 5.79; N, 3.22; O, 22.04

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 26020-55-3 (free base); 34522-46-8 (fumarate)  

Synonym: Oxetorone fumarate; Nocertone; L 6257; L-6257; L6257;

IUPAC/Chemical Name: (Z)-1-(benzo[6,7]oxepino[4,3-b]benzofuran-6(12H)-ylidene)-N,N-dimethylpropan-1-amine fumarate


InChi Code: InChI=1S/C21H21NO2.C4H4O4/c1-4-17(22(2)3)20-15-10-6-7-11-18(15)23-13-16-14-9-5-8-12-19(14)24-21(16)20;5-3(6)1-2-4(7)8/h5-12H,4,13H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b20-17-;2-1+

SMILES Code: CC/C(N(C)C)=C1C(OC2=CC=CC=C23)=C3COC4=CC=CC=C/14.O=C(O)/C=C/C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 435.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Deguigne M, Bruneau C, Touré A, Turcant A, Le Roux G. New evidence for oxetorone toxicity. Clin Toxicol (Phila). 2017 Feb;55(2):142-146. doi: 10.1080/15563650.2016.1267358. Epub 2016 Dec 14. PubMed PMID: 27967233.

2: Fathallah N, Chatti S, Azouz MM. [Lymphocytic colitis associated with oxetorone consumption]. Gastroenterol Clin Biol. 2010 Feb;34(2):154-5. doi: 10.1016/j.gcb.2009.12.001. Epub 2010 Jan 21. French. PubMed PMID: 20096517.

3: Ducros A. [National ranking exam. N64. What could fall at the exam?]. Rev Prat. 2008 Mar 15;58(5):549-50. French. PubMed PMID: 18524114.

4: Payen C, Patat AM, Pulce C, Descotes J. [Acute poisoning with oxetorone]. Therapie. 2006 Nov-Dec;61(6):548-50. French. PubMed PMID: 17348615.

5: Massiou H, Bousser MG. [Prophylactic drug treatment of migraine]. Rev Neurol (Paris). 2005 Jul;161(6-7):681-4. Review. French. PubMed PMID: 16141958.

6: Géraud G, Lantéri-Minet M, Lucas C, Valade D; French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004 Aug;26(8):1305-18. PubMed PMID: 15476911.

7: Pradalier A, Molitor JL, Campinos C. [Oxetorone and profuse sweating]. Therapie. 2003 Mar-Apr;58(2):166-7. French. PubMed PMID: 12942859.

8: Macaigne G, Boivin JF, Chayette C, Cheaib S, Deplus R. [Oxetorone-associated lymphocytic colitis]. Gastroenterol Clin Biol. 2002 May;26(5):537. French. PubMed PMID: 12122372.

9: Massiou H. [Prophylactic treatments of migraine]. Rev Neurol (Paris). 2000;156 Suppl 4:4S79-86. Review. French. PubMed PMID: 11139754.

10: Pradalier A. Hyperprolactinaemia and depression induced by oxetorone. Cephalalgia. 1996 Dec;16(8):560-1. PubMed PMID: 8980859.

11: Ollat H. [Serotonin agonists and antagonists in migraine]. Pathol Biol (Paris). 1992 Apr;40(4):389-96. Review. French. PubMed PMID: 1353874.

12: Richardet JP, Lons T, Mal F, Trinchet JC. [Chronic diarrhea under treatment with oxetorone]. Gastroenterol Clin Biol. 1992;16(1):100. French. PubMed PMID: 1537471.

13: Galerneau V, Petit J, Deghmani M, Leroy J, Droy JM, Leroy A, Oksenhendler G, Winckler C. Severe self-poisoning with oxetorone: report of one case. J Toxicol Clin Toxicol. 1990;28(1):111-6. PubMed PMID: 2381017.

14: Massiou H, Bousser MG. [Antimigrainous agents used in maintenance treatment]. Rev Prat. 1986 Jan 21;36(5):199-204. French. PubMed PMID: 2870558.

15: Barchewitz G, Vernant C, Mazue G, Binon F, Cier A, Tuchmann Duplessis H. Oxetorone-induced hyperprogesteronemia and the development of uterine decidual lesions in rats. Arzneimittelforschung. 1984;34(9):1007-10. PubMed PMID: 6542368.

16: Crémieux G, Serratrice G. [The present treatment of headaches (author's transl)]. Sem Hop. 1978 Oct 18-25;54(33-36):1055-8. French. PubMed PMID: 35831.

17: Florence J. [Clinical study of oxetorone in catamenial migraine. Comparison of two posological diagrams (author's transl)]. Schweiz Rundsch Med Prax. 1978 Sep 5;67(36):1323-7. French. PubMed PMID: 683962.

18: Dufresne JJ. [Double-blind study of oxetorone in patients with migraine or migrainous headache (author's transl)]. Schweiz Rundsch Med Prax. 1978 Aug 1;67(31):1148-52. German. PubMed PMID: 674095.

19: Rossi E, De Pascale A, Negrini P, Zanol M, Frigerio A. Oxetorone metabolism in vitro. J Chromatogr. 1978 May 11;152(1):228-3. PubMed PMID: 649745.

20: Wasserfallen JM. [Double-blind study with oxetorone in cephalalgia (author's transl)]. Schweiz Rundsch Med Prax. 1976 Aug 17;65(33):1021-4. French. PubMed PMID: 794862.